PDS Biotechnology Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PDSB research report →
Range $4 – $4
Price Chart
About the company
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates.
- CEO
- Frank K. Bedu-Addo
- IPO
- 2015
- Employees
- 21
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on PDSB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $43.39M
- P/E
- -1.44
- PEG
- -0.03
- P/S
- 0.00
- P/B
- 4.30
- EV/EBITDA
- -1.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -559.99%
- ROIC
- -189.14%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-31,543,959
- Net Income
- $-34,495,505+8.3%
- EPS
- $-0.74+28.2%
- OCF Growth
- +20.8%
- FCF Growth
- +20.8%
- 52W High
- $1.79
- 52W Low
- $0.20
- 50D MA
- $1.03
- 200D MA
- $0.84
- Beta
- 1.45
- RSI (14)
- 39
- Avg Volume
- 25.64M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
PDS Biotech highlighted a trial design amendment that could speed PDS0101 toward accelerated approval while lowering trial size and costs, alongside encouraging early PDS01ADC data and a stronger cash-usage profile in Q1 2026.· May 13, 2026
- VERSATILE-003 was amended to use progression-free survival as an interim primary endpoint, with overall survival still supporting full approval.
- Management said the amendment could shorten the trial, reduce costs, and lower enrollment from about 350 patients to about 250.
- First-quarter net loss improved to about $7.3 million, or $0.13 per share, from $8.5 million, or $0.21 per share a year ago.
- Cash was $21.7 million at March 31, 2026; R&D fell to $3.5 million and G&A to $3.1 million.
- PDS01ADC showed additional promise in colorectal and prostate cancer, and Stage 2 colorectal enrollment is now complete with more data expected by year-end.
For the quarter ended March 31, 2026, PDS Biotech reported a net loss of approximately $7.3 million, or $0.13 per basic and diluted share, versus a net loss of $8.5 million, or $0.21 per share, in the prior-year quarter. R&D expense was $3.5 million, down from $5.8 million, G&A was $3.1 million versus $3.3 million, total operating expenses were $6.5 million versus $9.1 million, and net interest expense was $0.8 million versus $0.6 million. Cash was $21.7 million at March 31, 2026. Management did not provide revenue guidance; instead, it said the VERSATILE-003 amendment could reduce trial duration and costs, lower the patient count from about 350 to about 250, and support an earlier path to accelerated approval. They also said additional colorectal cancer data from the fully enrolled cohort should be available by the end of the year.
Frank Bedu-Addo framed the quarter as one of meaningful clinical progress, especially around advancing PDS0101 and PDS01ADC. He emphasized that the new patent protections for PDS0101, combined with anticipated biologics exclusivity, extend market protection into the 2040s. His tone was constructive and execution-focused, ending by pointing to “meaningful opportunities ahead” across the 2026 priorities.
Lars Boesgaard focused on the improved cost profile and cash position. He said the quarter’s net loss improved to $7.3 million from $8.5 million a year earlier, driven by lower R&D and G&A expenses, and that the VERSATILE-003 amendment should reduce both external costs and internal operating expenses because of a shorter timeline. He also noted the protocol change reduced the planned patient count from approximately 350 to approximately 250, which should further lower trial costs. Cash was $21.7 million at March 31, 2026.
Analysts focused on the VERSATILE-003 restart, including what remains pending, whether subcutaneous Keytruda might be used later, and how the amendment changes the economics. Management said it is now moving through protocol amendment procedures and back to sites, which remained engaged during the pause; the current plan remains IV pembrolizumab, though a fully subcutaneous regimen could be considered in the future. Questions also covered the competitive HPV16 landscape and timing for colorectal data; management said there are still only two late-stage HPV16 head and neck studies in the space and expects additional colorectal cohort data by the end of the year.
The call suggested PDS0101 may have a more efficient regulatory path after the protocol amendment, with PFS potentially supporting accelerated approval while preserving OS for full approval. Management also said the trial should be smaller and cheaper, and that sites stayed engaged during the pause, which supports momentum. Early PDS01ADC results in colorectal and prostate cancer added to the sense that the broader pipeline has optionality.
The main risk remains that PDS0101 is still in a late-stage trial and final overall survival could take a long time, especially after management said median OS had increased from around 30 months to almost 40 months. Cash was $21.7 million, so funding remains an important backdrop even if the amendment reduces trial cost. In addition, management acknowledged that the current plan still depends on IV pembrolizumab and that a subcutaneous regimen is only a future possibility, not the present strategy.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.3%
- Shares Outstanding
- 55.82M
- Float Shares
- 54.85M
of shares held by institutions
53 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.95M | ▲ 49.51K |
| Vanguard Capital Management LLC | 1.67M | ▼ 30.97K |
| Militia Capital Management LLC | 1.66M | ▲ 1.33M |
| Renaissance Technologies LLC | 621.35K | ▲ 369.15K |
| Geode Capital Management, LLC | 616.39K | ▲ 29.25K |
| Blackrock, Inc. | 598.90K | ▼ 8.74K |
| Focus Partners Wealth | 551.76K | ▼ 90.42K |
| Quantinno Capital Management LP | 551.76K | ▼ 90.42K |
| Jane Street Group, LLC | 510.81K | ▲ 231.15K |
| Vanguard Fiduciary Trust Co | 357.14K | 0 |
| Citadel Advisors LLC | 323.80K | ▲ 323.80K |
| Blair William & Co/Il | 300.00K | 0 |
Held by 29 ETFs
Biggest fund positions in PDSB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | CONN GREGORY | other | 299,567 |
| Nov 16, 26 | BEDU-ADDO FRANK | other | 16,556,733 |
| Nov 16, 26 | BEDU-ADDO FRANK | other | 2,698,978 |
| Nov 16, 26 | Brown Spencer D. | other | 150,000 |
| Nov 16, 26 | PDS Biotechnology Corp | other | 299,567 |
| Nov 16, 26 | Shepard Kirk V. | other | 750,000 |
| Nov 16, 26 | Trochimiuk Janetta | other | 100,000 |
| Oct 18, 26 | Dawson John Andrew | other | 22,700 |
| Oct 18, 26 | Dawson John Andrew | other | 0 |
| Oct 18, 26 | Ramsdell Deborah | other | 22,700 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PDSB coverage
Recent articles, reports, and earnings notes.
No research on PDSB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PDSB report →PDS Biotech Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 13
PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds
globenewswire.com · Nov 10
PDS Biotechnology (PDSB) Just Flashed Golden Cross Signal: Do You Buy?
zacks.com · Nov 4
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
globenewswire.com · Oct 20
PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer
marketbeat.com · Oct 15
PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer Transcript
seekingalpha.com · Oct 15
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Oct 14
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
globenewswire.com · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.